Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HSD-016
Completed · Phase 1 · Has a placebo group
Conditions studied: Healthy Subjects
In brief
This is a single ascending dose study of HSD-016 to provide the initial assessment of the safety, tolerability, how the drug is absorbed and eliminated, and its effect on the body.
Key facts
- Study ID
- NCT00739232
- Run by
- Wyeth is now a wholly owned subsidiary of Pfizer
- People needed
- 74
- Starts
- 2008-09-01
- Expected to finish
- 2009-02-01
- Last updated by the study team
- 2009-08-03
Who can join
Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.
Where it is running
- Study site — Overland Park, Kansas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.